PD 154075

Subscribe to Selected New Research on PD 154075

2 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: a non-peptide tachykinin NK1 receptor antagonist; structure given in first source

Also Known As:

((2-benzofuran)-CH2OCO)-(R)-alpha-MeTrp-(S)-NHCH(CH3)Ph; 2-benzofuranylmethoxycarbonyl-alpha-methyltryptophan-N-(1-phenylethyl)amide; PD-154075

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Amino Acids: 8523

Essential Amino Acids: 334

Tryptophan: 3068

PD 154075: 2

Cyclic Amino Acids: 1

Aromatic Amino Acids: 226

Tryptophan: 3068

PD 154075: 2

Related Diseases

1.	Vomiting 02/26/1997 - "In conclusion, PD 154075 is a selective and specific high affinity NK1 receptor antagonist with good oral bioavailability which is effective against both acute and delayed emesis induced by cisplatin in the ferret." 02/26/1997 - "PD 154075 (1-30 mg/kg, i.p.) dose dependently antagonised the acute vomiting and retching in the ferret measured for 4 h following administration of cisplatin (10 mg/kg, i.p.) with a MED of 3 mg/kg. The administration of a lower dose of cisplatin (5 mg/kg, i.p.) in the ferret induces both an acute (day 1) and delayed (days 2 and 3) phase of emesis" 02/26/1997 - "The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret." 02/26/1997 - "The activity of a selective tachykinin NK1 receptor antagonist, PD 154075 ([(2-benzofuran)-CH2OCO]-(R)-alpha-MeTrp-(S)-NHCH(CH3) Ph), was examined in radioligand binding studies, in a [Sar9,Met(O2)11]substance P-induced foot-tapping model in the gerbil, and in cisplatin-induced acute and delayed emesis in the ferret" Get all the results and reference details, order at left...
2.	Postoperative Pain 03/05/1998 - "Evaluation of PD 154075, a tachykinin NK1 receptor antagonist, in a rat model of postoperative pain." Get all the results and reference details, order at left...
3.	Hypersensitivity (Allergy) 03/05/1998 - "When administered 30 min before surgery, PD 154075 dose-dependently (3-100 mg/kg, s.c.) prevented the development of thermal and mechanical hypersensitivity with respective minimum effective doses of 10 and 30 mg/kg. These antihypersensitivity effects lasted for 72 h" 03/05/1998 - "PD 154075 antagonised thermal hypersensitivity induced by intrathecal administration of substance P, over the same dose range that blocked surgical hypersensitivity" Get all the results and reference details, order at left...
3 Diseases and 2 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Tachykinins
3.	Substance P
4.	benzofuran
4 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>